Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Streptococcus pneumoniae Capsular Polysaccharides (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) (CPS)
- Target
- CPS
- Molecular classification
- Polysaccharide, Capsular Antigen
01
Overview
Streptococcus pneumoniae capsular polysaccharides (CPS) are high-molecular-weight carbohydrate polymers that form a capsule surrounding the bacterial cell. This capsule is the dominant surface structure of S. pneumoniae and is essential for its virulence by shielding the bacteria from immune responses. The listed serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) are among the most common causes of invasive pneumococcal disease and are targeted by current pneumococcal vaccines. Each serotype has a unique chemical structure, and immunity to one serotype does not confer protection against others. Vaccination strategies rely on purified CPS or CPS conjugated to protein carriers to induce serotype-specific immunity.
- Other names
- Pneumococcal Capsular PolysaccharidesS. pneumoniae CPSCapsular Polysaccharide Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F
02
Mechanism of action
Antibody-mediated opsonization and phagocytosis of Streptococcus pneumoniae; Induction of serotype-specific immunity
03
Biological functions
Immune evasionVirulenceCapsule formation
04
Disease associations
InfectionPneumoniaMeningitisBacteremia
05
Safety considerations
Serotype replacement post-vaccinationLimited coverage of all circulating serotypesPotential for vaccine failure in immunocompromised individuals
06
Interacting drugs
PCV13 (Prevnar 13)
3 more in the full profile.
07
Biomarkers
Capsular serotype identification for epidemiological surveillanceAntibody titers against specific serotypes post-vaccination
Beyond the preview
Go deeper on Streptococcus pneumoniae Capsular Polysaccharides (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) (CPS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus pneumoniae Capsular Polysaccharides (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) (CPS).